Last data update: May 06, 2024. (Total: 46732 publications since 2009)
Records 1-5 (of 5 Records) |
Query Trace: Benenson G[original query] |
---|
The Check and Report Ebola (CARE+) Program to monitor travelers for Ebola after arrival to the United States, 2014-2016
Joseph HA , Wojno AE , Winter K , Grady-Erickson O , Hawes E , Benenson GA , Lee A , Cetron M . Public Health Rep 2019 134 (6) 592-598 The 2014-2016 Ebola epidemic in West Africa influenced how public health officials considered migration and emerging infectious diseases. Responding to the public's concerns, the US government introduced enhanced entry screening and post-arrival monitoring by public health authorities to reduce the risk of importation and domestic transmission of Ebola while continuing to allow travel from West Africa. This case study describes a new initiative, the Check and Report Ebola (CARE+) program that engaged travelers arriving to the United States from countries with Ebola outbreaks. The Centers for Disease Control and Prevention employed CARE ambassadors, who quickly communicated with incoming travelers and gave them practical resources to boost their participation in monitoring for Ebola. The program aimed to increase travelers' knowledge of Ebola symptoms and how to seek medical care safely, increase travelers' awareness of monitoring requirements, reduce barriers to monitoring, and increase trust in the US public health system. This program could be adapted for use in future outbreaks that involve the potential importation of disease and require the education and active engagement of travelers to participate in post-arrival monitoring. |
Health education workforce: Opportunities and challenges
Bruening RA , Coronado F , Auld ME , Benenson G , Simone PM . Prev Chronic Dis 2018 15 E89 Public health is facing unprecedented opportunities and challenges. Health departments face shifts from less clinical service delivery to increased population-based services to address the growing burden of chronic diseases (eg, obesity prevention, tobacco and drug use prevention) and new responsibilities to collaborate with other sectors in conducting community needs assessments and data sharing (1–3). State and local health departments continue to be challenged by health policy changes, reduced budgets, and difficulty recruiting and retaining staff (2). These challenges need to be met with a public health workforce of adequate size, composition, distribution, and skills. Formally trained health educators are an important but often underutilized part of the workforce needed to meet such challenges. Although various health workers inform the public, many employers are unaware of the professional training and roles of health educators (4). Health educators (also referred to as health education specialists) address chronic and other conditions by applying their competencies to the design and execution of behavioral health and policy or systems interventions (4). This essay highlights how the skill sets of health educators can address current and future public health challenges, the need for improved health educator workforce data, and a call to action for various stakeholders to optimally deploy health educators to improve the public’s health. |
Travel and border health measures to prevent the international spread of Ebola
Cohen NJ , Brown CM , Alvarado-Ramy F , Bair-Brake H , Benenson GA , Chen TH , Demma AJ , Holton NK , Kohl KS , Lee AW , McAdam D , Pesik N , Roohi S , Smith CL , Waterman SH , Cetron MS . MMWR Suppl 2016 65 (3) 57-67 During the 2014-2016 Ebola virus disease (Ebola) epidemic in West Africa, CDC implemented travel and border health measures to prevent international spread of the disease, educate and protect travelers and communities, and minimize disruption of international travel and trade. CDC staff provided in-country technical assistance for exit screening in countries in West Africa with Ebola outbreaks, implemented an enhanced entry risk assessment and management program for travelers at U.S. ports of entry, and disseminated information and guidance for specific groups of travelers and relevant organizations. New and existing partnerships were crucial to the success of this response, including partnerships with international organizations, such as the World Health Organization, the International Organization for Migration, and nongovernment organizations, as well as domestic partnerships with the U.S. Department of Homeland Security and state and local health departments. Although difficult to assess, travel and border health measures might have helped control the epidemic's spread in West Africa by deterring or preventing travel by symptomatic or exposed persons and by educating travelers about protecting themselves. Enhanced entry risk assessment at U.S. airports facilitated management of travelers after arrival, including the recommended active monitoring. These measures also reassured airlines, shipping companies, port partners, and travelers that travel was safe and might have helped maintain continued flow of passenger traffic and resources needed for the response to the affected region. Travel and border health measures implemented in the countries with Ebola outbreaks laid the foundation for future reconstruction efforts related to borders and travel, including development of regional surveillance systems, cross-border coordination, and implementation of core capacities at designated official points of entry in accordance with the International Health Regulations (2005). New mechanisms developed during this response to target risk assessment and management of travelers arriving in the United States may enhance future public health responses. The activities summarized in this report would not have been possible without collaboration with many U.S. and international partners (http://www.cdc.gov/vhf/ebola/outbreaks/2014-west-africa/partners.html). |
Airport exit and entry screening for Ebola - August-November 10, 2014
Brown CM , Aranas AE , Benenson GA , Brunette G , Cetron M , Chen TH , Cohen NJ , Diaz P , Haber Y , Hale CR , Holton K , Kohl K , Le AW , Palumbo GJ , Pearson K , Phares CR , Alvarado-Ramy F , Roohi S , Rotz LD , Tappero J , Washburn FM , Watkins J , Pesik N . MMWR Morb Mortal Wkly Rep 2014 63 (49) 1163-7 In response to the largest recognized Ebola virus disease epidemic now occurring in West Africa, the governments of affected countries, CDC, the World Health Organization (WHO), and other international organizations have collaborated to implement strategies to control spread of the virus. One strategy recommended by WHO calls for countries with Ebola transmission to screen all persons exiting the country for "unexplained febrile illness consistent with potential Ebola infection." Exit screening at points of departure is intended to reduce the likelihood of international spread of the virus. To initiate this strategy, CDC, WHO, and other global partners were invited by the ministries of health of Guinea, Liberia, and Sierra Leone to assist them in developing and implementing exit screening procedures. Since the program began in August 2014, an estimated 80,000 travelers, of whom approximately 12,000 were en route to the United States, have departed by air from the three countries with Ebola transmission. Procedures were implemented to deny boarding to ill travelers and persons who reported a high risk for exposure to Ebola; no international air traveler from these countries has been reported as symptomatic with Ebola during travel since these procedures were implemented. |
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand
Rerks-Ngarm S , Pitisuttithum P , Nitayaphan S , Kaewkungwal J , Chiu J , Paris R , Premsri N , Namwat C , de Souza M , Adams E , Benenson M , Gurunathan S , Tartaglia J , McNeil JG , Francis DP , Stablein D , Birx DL , Chunsuttiwat S , Khamboonruang C , Thongcharoen P , Robb ML , Michael NL , Kunasol P , Kim JH , MOPH-TAVEG Investigators . N Engl J Med 2009 361 (23) 2209-20 BACKGROUND: The development of a safe and effective vaccine against the human immunodeficiency virus type 1 (HIV-1) is critical to pandemic control. METHODS: In a community-based, randomized, multicenter, double-blind, placebo-controlled efficacy trial, we evaluated four priming injections of a recombinant canarypox vector vaccine (ALVAC-HIV [vCP1521]) plus two booster injections of a recombinant glycoprotein 120 subunit vaccine (AIDSVAX B/E). The vaccine and placebo injections were administered to 16,402 healthy men and women between the ages of 18 and 30 years in Rayong and Chon Buri provinces in Thailand. The volunteers, primarily at heterosexual risk for HIV infection, were monitored for the coprimary end points: HIV-1 infection and early HIV-1 viremia, at the end of the 6-month vaccination series and every 6 months thereafter for 3 years. RESULTS: In the intention-to-treat analysis involving 16,402 subjects, there was a trend toward the prevention of HIV-1 infection among the vaccine recipients, with a vaccine efficacy of 26.4% (95% confidence interval [CI], -4.0 to 47.9; P=0.08). In the per-protocol analysis involving 12,452 subjects, the vaccine efficacy was 26.2% (95% CI, -13.3 to 51.9; P=0.16). In the modified intention-to-treat analysis involving 16,395 subjects (with the exclusion of 7 subjects who were found to have had HIV-1 infection at baseline), the vaccine efficacy was 31.2% (95% CI, 1.1 to 51.2; P=0.04). Vaccination did not affect the degree of viremia or the CD4+ T-cell count in subjects in whom HIV-1 infection was subsequently diagnosed. CONCLUSIONS: This ALVAC-HIV and AIDSVAX B/E vaccine regimen may reduce the risk of HIV infection in a community-based population with largely heterosexual risk. Vaccination did not affect the viral load or CD4+ count in subjects with HIV infection. Although the results show only a modest benefit, they offer insight for future research. (ClinicalTrials.gov number, NCT00223080.) Copyright 2009 Massachusetts Medical Society. |
- Page last reviewed:Feb 1, 2024
- Page last updated:May 06, 2024
- Content source:
- Powered by CDC PHGKB Infrastructure